Wacker Chemie

A precipitous step deeper into the CDMO business

23/11/20 -"Wacker's Biosolutions business has become a partner of choice for German mRNA player CureVac. Currently, the technology transfer for the production of CureVac's COVID-19 vaccine candidate is being ..."

PDF page sample
Pages
53
Language
English
Published on
23/11/20
Download
You may also be interested by these reports :
12/03/26
The merger is largely integrated, with portfolio clean-up nearly complete. The focus now shifts to execution. At its Investor Day, DSM-Firmenich ...
12/03/26
Wacker’s earnings were largely expected following its detailed FY2025 preliminary release in January 2026. Investors reacted positively to the 2026 ...
04/03/26
Symrise reported a robust FY2025 performance and is strengthening its foundations as demand gradually normalises. Through the ONE SYM transformation ...
04/03/26
The Middle East conflict has driven oil and gas prices higher, pressuring chemical companies through elevated feedstock and energy costs. Upstream ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO